Welcome to our dedicated page for Abeona Therapeut SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Abeona Therapeutics Inc. (ABEO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Abeona is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, and its filings offer detailed insight into the business, including the commercialization of ZEVASKYN® (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa (RDEB) and the development of AAV-based gene therapies for ophthalmic conditions.
Investors can review current reports on Form 8-K, where Abeona reports material events such as quarterly financial results, operational updates on ZEVASKYN manufacturing and launch activities, and transactions like the sale of a Rare Pediatric Disease Priority Review Voucher awarded upon FDA approval of ZEVASKYN. These filings also confirm that Abeona’s common stock, with a par value of $0.01 per share, trades on The Nasdaq Capital Market under the symbol ABEO.
In addition to 8-Ks, users can access annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for information on Abeona’s research and development spending, selling, general and administrative expenses related to the ZEVASKYN launch, cash and investment balances, debt obligations, and risk factor disclosures relevant to its gene therapy programs and manufacturing operations.
Stock Titan enhances these documents with AI-powered summaries that help explain key sections of lengthy filings, such as revenue descriptions, cost structures, and updates on regulatory interactions. The platform also surfaces insider transaction reports on Form 4 when filed, enabling users to track equity awards and other changes in beneficial ownership by Abeona’s officers and directors.
By combining real-time EDGAR updates with AI-generated highlights, this ABEO filings page is designed to make Abeona’s complex biopharmaceutical and gene therapy disclosures more accessible to investors, analysts, and other interested readers.
Abeona Therapeutics (ABEO) reported Q3 2025 results, reflecting the first months after FDA approval of ZEVASKYN for RDEB. The quarter showed a net loss of $5.2 million$30.3 million loss a year ago, as commercialization spending ramped. Year-to-date, the company recorded $91.6 million in net income, largely from a $152.4 million gain on the sale of a Priority Review Voucher.
Liquidity strengthened: cash and cash equivalents were $82.9 million and short‑term investments were $124.2 million as of September 30, 2025. Stockholders’ equity rose to $171.2 million. Q3 operating expenses included R&D $4.2 million and SG&A $19.3 million as the company built out commercial infrastructure and manufacturing capacity. Inventory totaled $4.9 million (raw materials). Warrant liabilities declined to $22.6 million. The company maintained a $20.0 million senior term loan; an amendment on July 18, 2025 reduced the interest rate to a fixed 11.75% and included issuance of 16,473 new warrants. Common shares outstanding were 54,191,361 as of November 7, 2025.
Abeona Therapeutics Inc. (ABEO) furnished quarterly results information. The company reported that it issued a press release regarding its financial results for the quarter ended September 30, 2025, and furnished it under Item 2.02.
The full text of the release is included as Exhibit 99.1. As stated, the information under Item 2.02 and Exhibit 99.1 is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act, and is not incorporated by reference except as expressly set forth by specific reference.
Abeona Therapeutics (ABEO) CEO and Director Vishwas Seshadri reported a Form 4 transaction. He sold 249 shares of common stock on 10/16/2025 at $5.485 per share, a sale described as to cover tax obligations from the vesting of restricted stock awards.
Following the transaction, he beneficially owns 1,189,818 shares, held directly.
Nantahala Capital Management, LLC and two managers report shared beneficial ownership of 5,184,662 shares of Abeona Therapeutics, representing
A Nantahala Capital Partners Schedule 13G filed for ABEONA THERAPEUTICS INC. reports shared beneficial ownership of
ABEO Form 4 summary: Brendan M. O'Malley, Senior Vice President and Chief Legal Officer of Abeona Therapeutics (ABEO), reported a sale of 9,366 shares of common stock on 09/29/2025 at a weighted average price of $5.3935 per share. After the sale, he beneficially owns 350,763 shares. The filing states the sale was executed to cover tax obligations arising from the vesting of restricted stock awards and that the reported price reflects multiple transactions ranging from $5.35 to $5.46.
Insider sales reported by Vishwas Seshadri, CEO and Director of Abeona Therapeutics (ABEO). The Form 4 shows two non-derivative sales: 19,274 shares sold on 09/29/2025 at a weighted average price of $5.3935 to cover tax obligations from restricted stock vesting, and 25,000 shares sold on 09/30/2025 at a weighted average price of $5.2372 under an existing Rule 10b5-1 trading plan. The reporting persons beneficial ownership decreased from 1,215,067 shares to 1,190,067 shares following these transactions. The filing is signed by Vishwas Seshadri on 10/01/2025.
Joseph Walter Vazzano, Chief Financial Officer of ABEONA THERAPEUTICS INC. (ABEO), reported the sale of 9,035 shares of common stock on 09/29/2025. The disclosed weighted-average price was $5.3935 per share, with individual trade prices ranging between $5.35 and $5.46. The filing states the shares were sold to cover tax obligations arising from the vesting of restricted stock awards. After the reported sale, the reporting person beneficially owned 453,631 shares, held directly. The Form 4 reflects a routine tax-related disposition rather than a market-timing or strategic sale.
Form 144 notice for Abeona Therapeutics, Inc. (ABEO): The filer reports a proposed sale of 44,274 shares of common stock through Stifel Nicolaus & Company, to be executed on 09/29/2025 on Nasdaq with an aggregate market value of $238,792.00. The shares were acquired as 38,800 restricted stock units on 09/28/2025 and payment is noted as cash on 09/29/2025. The filing shows 51,156,736 shares outstanding for the issuer. The form also discloses a sale by Vishwas Seshadri of 69,420 shares on 07/09/2025 for $406,503.00. The notice contains the standard insider representation regarding material nonpublic information.
A Form 144 notice shows a proposed sale of 9,366 shares of common stock of Abeona Therapeutics, Inc. (ticker ABEO) by Brendan O'Malley. The shares are listed with an aggregate market value of $50,516.00 and the filer lists Nasdaq as the exchange. The filing states the shares were acquired as Restricted Stock Units on 09/29/2025 and payment is shown as cash. The table of recent sales also records a sale by Brendan O'Malley of 9,366 shares on 09/22/2025 for gross proceeds of $50,515.00. The notice includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Abeona Therapeut (ABEO)?
What is the market cap of Abeona Therapeut (ABEO)?
